COREY FINCH: Open Payments
NPI 1407903644 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$596 in 19 payments from 12 companies in 2025. Trend: 2023 $992 · 2024 $435 · 2025 $596
Food & beverage: $498Education: $98
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $196 |
| Neurocrine BioSciences, Inc. | 1 | $136 |
| Acarix USA Inc. | 1 | $44 |
| PFIZER INC. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $34 |
| Corcept Therapeutics | 1 | $31 |
| SK Life Science, Inc. | 1 | $24 |
| UCB, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
Products named: INGREZZA, AUSTEDO XR, REXULTI, CADScor System, NURTEC ODT, Korlym, Briviact, COBENFY.
Industry payments across OK — which companies pay providers there.
